Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12612001078842
Ethics application status
Approved
Date submitted
30/08/2012
Date registered
9/10/2012
Date last updated
9/10/2012
Type of registration
Retrospectively registered
Titles & IDs
Public title
The influence on blood clotting of the consumption of fish oils.
Query!
Scientific title
The Effects of therapeutic doses of Fish Oil on Coagulation Studies in healthy volunteers
Query!
Secondary ID [1]
281124
0
Nil
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
EFOCS (Effects of Fish Oil On Coagulation Study)
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Potential Coagualopathy caused by fish oil
287293
0
Query!
Condition category
Condition code
Blood
287624
287624
0
0
Query!
Clotting disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Comparison of two groups of healthy volunteers consuming either 3grams or 12grams per day of Fish Oil capsules.
Fish Oil is consumed for four weeks, and then discontinued for four weeks
Query!
Intervention code [1]
285582
0
Treatment: Drugs
Query!
Comparator / control treatment
Dose comparison of 3grams of fishoil against 12 grams of fish oil per day for four weeks
Query!
Control group
Dose comparison
Query!
Outcomes
Primary outcome [1]
287872
0
Caogualtion studies- Thromboelastography (TEG/ROTEM)
Query!
Assessment method [1]
287872
0
Query!
Timepoint [1]
287872
0
Samples at 0, 1 and 4 weeks of fishoil consumption and 1 and 4 weeks after cessation of fishoil
Query!
Secondary outcome [1]
298969
0
Platelet microparticle concentrations
Query!
Assessment method [1]
298969
0
Query!
Timepoint [1]
298969
0
Samples at 0, 1 and 4 weeks of fishoil consumption and 1 and 4 weeks after cessation of fishoil
Query!
Eligibility
Key inclusion criteria
ASA 1 or 2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
50
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Patients taking any regular medication (exc oral contraceptive)
Confirmed coagulation disorder (pathological or drug induced)
BMI >35
Documented allergy to O3FA
Documented pregnancy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation not concealed to volunteer or enrolment team. Allocation concealed to laboratory staff analyzing blood.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Pharmacodynamics
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Date of first participant enrolment
Anticipated
20/04/2012
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
32
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
285904
0
Hospital
Query!
Name [1]
285904
0
Royal Perth Hospital Medical Research Foundation
Query!
Address [1]
285904
0
Wellington Street Campus
Perth
Western Australia
6000
Query!
Country [1]
285904
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Royal Perth Hospital
Query!
Address
Wellington Street Campus
Perth
Western Australia
6000
Query!
Country
Australia
Query!
Secondary sponsor category [1]
284726
0
None
Query!
Name [1]
284726
0
Query!
Address [1]
284726
0
Query!
Country [1]
284726
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
287931
0
Royal Perth Hospital Human Research Ethics Committee
Query!
Ethics committee address [1]
287931
0
Wellington Street Campus
Perth
WA
6000
Query!
Ethics committee country [1]
287931
0
Australia
Query!
Date submitted for ethics approval [1]
287931
0
Query!
Approval date [1]
287931
0
28/02/2012
Query!
Ethics approval number [1]
287931
0
EC2011/143
Query!
Summary
Brief summary
There is strong evidence that the use of omega-3 fatty acids (O3FAs) reduces cardiovascular
risk in certain populations. Major bodies such as the Australian National Heart Foundation
(NHF), American Heart Association (AHA) and British Heart Foundation (BHF) have
recommended their use which has lead to widespread uptake by the general population. As their
use becomes more prevalent, increasing numbers of patients are presenting for surgery whilst
taking O3FAs.
Amongst the potential adverse effects of O3FAs, there is theoretical suspicion that these
compounds may reduce blood coagulability. Both the AHA and BHF have issued cautionary
statements regarding this. This is of clinical interest as it could increase both perioperative blood
loss, and the risk of serious complications with certain anaesthetic techniques. Previous studies
investigating this effect have used older laboratory measures of coagulation which show little
correlation with clinical bleeding risk.
In the absence of good evidence disproving their theoretical suspicions, many surgeons and
anaesthetists may advise patients to discontinue fish oils for several days prior to surgery.
Given that the perioperative period is a time of increased cardiovascular risk, this decision is not
without risk to the patient.
We plan to investigate the effects of two different doses of fish oils on blood coagulation as
measured by several laboratory tests which have been shown to have a much stronger
correlation with clinical bleeding risk than traditional tests used in earlier studies.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
34640
0
Query!
Address
34640
0
Query!
Country
34640
0
Query!
Phone
34640
0
Query!
Fax
34640
0
Query!
Email
34640
0
Query!
Contact person for public queries
Name
17887
0
Tomas Corcoran
Query!
Address
17887
0
Department of Anaesthesia and Pain medicine
Royal Perth Hospital
Wellington Street Campus
Perth
WA
6000
Query!
Country
17887
0
Australia
Query!
Phone
17887
0
+61 (08)9224 2244
Query!
Fax
17887
0
Query!
Email
17887
0
[email protected]
Query!
Contact person for scientific queries
Name
8815
0
Tomas Corcoran
Query!
Address
8815
0
Department of Anaesthesia and Pain medicine
Royal Perth Hospital
Wellington Street Campus
Perth
WA
6000
Query!
Country
8815
0
Australia
Query!
Phone
8815
0
+61 (08)9224 2244
Query!
Fax
8815
0
Query!
Email
8815
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF